Trinity Biotech (TRIB) EBITDA (2016 - 2024)
Historic EBITDA for Trinity Biotech (TRIB) over the last 16 years, with Q4 2024 value amounting to -$11.5 million.
- Trinity Biotech's EBITDA fell 20465.73% to -$11.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$21.2 million, marking a year-over-year increase of 2175.97%. This contributed to the annual value of -$21.2 million for FY2024, which is 2174.15% up from last year.
- According to the latest figures from Q4 2024, Trinity Biotech's EBITDA is -$11.5 million, which was down 20465.73% from -$2.6 million recorded in Q3 2024.
- In the past 5 years, Trinity Biotech's EBITDA ranged from a high of $9.1 million in Q3 2020 and a low of -$14.9 million during Q2 2023
- In the last 5 years, Trinity Biotech's EBITDA had a median value of -$2.2 million in 2022 and averaged -$2.0 million.
- In the last 5 years, Trinity Biotech's EBITDA soared by 58154.54% in 2020 and then tumbled by 154884.55% in 2022.
- Over the past 5 years, Trinity Biotech's EBITDA (Quarter) stood at $9.1 million in 2020, then tumbled by 93.79% to $563000.0 in 2021, then tumbled by 1548.85% to -$8.2 million in 2022, then surged by 53.67% to -$3.8 million in 2023, then tumbled by 204.66% to -$11.5 million in 2024.
- Its EBITDA was -$11.5 million in Q4 2024, compared to -$2.6 million in Q3 2024 and -$4.1 million in Q2 2024.